Kinase Regulators

Product #

Image

Description

Biochem/physiol Actions

solubility

Add to Cart

D8907 1,2-Dioctanoylethylene glycol ~99% Potent inhibitor of sn-1,2-diacylglycerol phosphorylation in vitro.
 
A4978 Alendronate sodium trihydrate ≥97% (NMR), powder Alendronate sodium trihydrate is a bone resorption inhibitor; farnesyl diphosphate synthase inhibitor (IC50 = 460 nM); CD45 protein tyrosine phosphatase inhibitor.
water, double-distilled: 10 mg/mL
D5794 Diacylglycerol Kinase Inhibitor II solid Diacylglycerol kinase inhibitor. Inhibits formation of [38P]1-Oleoyl-2-acetylglyceryl-3-phosphoric acid (OAPA) in red blood cell membranes: IC50 = 3.3 μM.
0.1 M HCl: slightly soluble
0.1 M NaOH: slightly soluble
DMSO: soluble
H2O: insoluble
ethanol: soluble
ethyl acetate: soluble
D5919 Diacylglycerol Kinase Inhibitor I solid Diacylglycerol kinase inhibitor. Inhibits formation of [38P]1-Oleoxyl-2-acetylglyceryl-3-phosphoric acid (OAPA) in red blood cell membranes: IC50 = 3.3 μM.
0.1 M HCl: slightly soluble
0.1 M NaOH: slightly soluble
DMSO: soluble
H2O: insoluble
ethanol: soluble
ethyl acetate: soluble
I5784 Ibandronate sodium salt ≥97% (NMR), solid Ibandronate sodium inhibits farnesyl diphosphate synthase (IC50 = 20 nM). Ibandronate sodium is also a bone resorption inhibitor. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.
H2O: >10 mg/mL
P2371 Pamidronate disodium salt hydrate ≥95% (NMR), solid Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM).
H2O: 28 mg/mL
R2028 RHC 80267 ≥98% (HPLC), solid RHC 80267 is a diacylglycerol (DAG) lipase inhibitor and an important second messenger in signal transduction pathways. RHC 80267 is generated by the hydrolysis of phosphatidylinositol (PI) and bPC by phospholipase C (PLC). DAG mediates the actions of a large number of hormones and cytokines by activating protein kinase C (PKC). A sustained elevation in intracellular DAG may cause neoplastic transformation.
DMSO: 9 mg/mL
SML0650   Risedronate sodium ≥97% (NMR) Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.
H2O: 5 mg/mL clear (warmed)
SML0223 Zoledronic acid monohydrate ≥98% (HPLC) Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.
H2O: ≥2 mg/mL